<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04541966</url>
  </required_header>
  <id_info>
    <org_study_id>RECHMPL20_0479</org_study_id>
    <nct_id>NCT04541966</nct_id>
  </id_info>
  <brief_title>What Happens to First Trimester Nuchal Translucency</brief_title>
  <official_title>What Happens to First Trimester Nuchal Translucency Greater Than or Equal 99Ã¨me Percentile and Inferior 3.5 mm</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Montpellier</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Montpellier</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      First trimester nuchal translucency is a call point for genetic abnormalities and birth&#xD;
      defects. Nuchal translucency varies with LCC and therefore with gestational age as described&#xD;
      by Chung et al who created a 99th percentile curve of nuchal translucency versus LCC. The&#xD;
      majority of centers use the 3.5 mm cutoff as the 99th percentile instead of using nuchal&#xD;
      translucency based on LCC. The objective of this study is to compare the fate of nuchal&#xD;
      hyperclites&gt; = 99th p but &lt;3.5mm versus 3.5mm. For this the investigators have studied the&#xD;
      ultrasound and genetic abnormalities. The investigators were also interested in the pregnancy&#xD;
      outcomes and the percentage of pregnancies in the group&gt; = 99th p and &lt;3.5mm that would have&#xD;
      been sampled for a high combined risk for trisomy 21, and therefore to determine the benefit&#xD;
      of a systematic sample. for HCN as well as the interest of performing an ACPA that would not&#xD;
      be performed on a sample with a high risk of trisomy 21.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 1, 2020</start_date>
  <completion_date type="Actual">September 1, 2020</completion_date>
  <primary_completion_date type="Actual">May 1, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Pregnancies without ultrasound or genetic abnormalities</measure>
    <time_frame>immediate antenatal and postnatal period</time_frame>
    <description>Pregnancies without ultrasound or genetic abnormalities</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ACPA interest</measure>
    <time_frame>immediate antenatal and postnatal period</time_frame>
    <description>ACPA interest</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>percentage of samples for high risk combined for trisomy 21</measure>
    <time_frame>immediate antenatal and postnatal period</time_frame>
    <description>percentage of samples for high risk combined for trisomy 21</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pregnancy outcomes</measure>
    <time_frame>immediate antenatal and postnatal period</time_frame>
    <description>Pregnancy outcomes</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">230</enrollment>
  <condition>Nuchal Translucency</condition>
  <arm_group>
    <arm_group_label>Nuchal translucency&gt; = 99th percentile and &lt;3.5mm</arm_group_label>
    <description>Nuchal translucency&gt; = 99th percentile and &lt;3.5mm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nuchal translucency&gt; = 3.5 mm</arm_group_label>
    <description>Nuchal translucency&gt; = 3.5 mm</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Single pregnancies with nuchal hyperclarity in the first trimester&gt; = 99th percentile at&#xD;
        the Montpellier University Hospital with early pregnancy between January 2017 and December&#xD;
        2019.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
        nuchal translucency&gt; = 99th percentile&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
        - multiple pregnancies&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Florent FUCHS, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Montpellier</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Uhmontpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>September 1, 2020</study_first_submitted>
  <study_first_submitted_qc>September 1, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 9, 2020</study_first_posted>
  <last_update_submitted>September 8, 2020</last_update_submitted>
  <last_update_submitted_qc>September 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ultrasound abnormalities</keyword>
  <keyword>Genetic abnormalities</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>NC</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

